Novartis starts FortiHFy clinical program to study heart failure
Novartis announced FortiHfy clinical program aimed at studying heart failure disease with as many as 40 active or planned clinical studies.
The studies have been designed to give an array of additional data on reduction in symptoms, efficacy, quality of life benefits, to improve understanding about heart failure and to test the real world evidence for Novartis' heart failure medicine Entresto (sacubitril/valsartan).
Click on this link for more information.
